Mostrando 6 resultados de: 6
Filtros aplicados
Subtipo de publicación
Article(6)
Publisher
Cancer Biology and Therapy(2)
BMC Cancer(1)
British Journal of Cancer(1)
Cancer Research(1)
Molecular and Cellular Biochemistry(1)
Área temáticas
Enfermedades(6)
Farmacología y terapéutica(5)
Bioquímica(2)
Ginecología, obstetricia, pediatría, geriatría(1)
Medicina y salud(1)
Origen
google(2)
Antitumor effect of a novel proapoptotic peptide that impairs the phosphorylation by the protein kinase 2 (casein kinase 2)
ArticleAbstract: Protein Kinase (casein kinase 2, CK2) is a serine-threonine kinase that is frequently dysregulated iPalabras claves:Autores:Acevedo B.E., Alonso D.F., Falcón-Cama V., López-Mola E., Mendoza O., Perea-Rodríguez S.E., Puchades Y., Reyes O., Santiago Nelson Vispo, Santos-Savio A., Silva R., Torrens I.Fuentes:scopus1E10 anti-idiotype vaccine in non-small cell lung cancer: Experience in stage IIIb/IV patients
ArticleAbstract: Conventional treatment of non-small cell lung cancer (NSCLC) has apparently reached a plateau of effPalabras claves:Anti-idiotype antibody, Cancer Vaccines, Clinical study, immunotherapyAutores:Aguirre F., Alfonso S., Alonso D.F., Barroso M.C., Carmen Elena Viada, De La Torre A.V., Díaz R.M., Gabri M.R., Gómez R., Hernández A.M., Macías A.E., Pérez K., Pérez R., Rodríguez J., Santiesteban E.R., Suárez E., Toledo D., Vázquez A.M.Fuentes:scopusCIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo
ArticleAbstract: Protein Kinase CK2 is a serine-threonine kinase frequently deregulated in many human tumors. Here, wPalabras claves:apoptosis, Cancer targeted therapy, Casein kinase 2Autores:Acevedo B.E., Alonso D.F., Ariosa J., Bacardí D.M., Baladron I., Besada-Pérez V., Betancourt L., Castellanos L.R., Cosme K., Cruz M., Díaz A., Falcón-Cama V., Farina H., Garay H.E., Gil J., Gómez D., Gómez R., González L.J., Hernández I., Herrera L., López C., López-Mola E., López-Saura P.A., Marcelo J.L., Mendoza O., Perea-Rodríguez S.E., Perera Y., Puchades Y., Reyes O., Rodriguez A., Sánchez A., Santana A., Serrano J.M., Sigman H., Silva R., Solares M., Thelvia I. Ramos Gómez, Valenzuela-Silva C.M.Fuentes:googlescopusActive immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: Report of a phase I trial
ArticleAbstract: 1E10 is an anti-idiotype murine monoclonal antibody (Ab2 MAb) specific to an Ab1 MAb which reacts wiPalabras claves:Anti-idiotype antibody, Cancer Vaccines, Clinical study, immunotherapyAutores:Alfonso A.M., Alonso D.F., Bárbara Wilkinson, Combet T., De La Torre A.V., Díaz A., Díaz R.M., Gabri M.R., Neninger Vinageras E., Pérez R., Rives R., Saurez G., Vázquez A.M.Fuentes:scopusOptimizing CIGB-300 intralesional delivery in locally advanced cervical cancer
ArticleAbstract: Background:We conducted a phase 1 trial in patients with locally advanced cervical cancer by injectiPalabras claves:B23/nucleophosmin, Cervical Cancer, CIGB-300, tumour uptakeAutores:Acevedo B.E., Alonso D.F., Ancízar J.A., Baladron I., Casacó C.A., Coca M.A., García I., Gómez R., González L.J., González Y.M., Hernández I., I. Howland-Álvarez, López-Saura P.A., Martínez Y.M., Molina L., Perea-Rodríguez S.E., Perera A., Perera Y., Prats A., Reyes V., Solares M., Torres L.A., Valenzuela-Silva C.M.Fuentes:scopusSafety and preliminary efficacy data of a novel Casein Kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies
ArticleAbstract: Background: Cervical cancer is now considered the second leading cause of death among women worldwidPalabras claves:Autores:Acevedo B.E., Alonso D.F., Baladron I., Castillo D., Díaz A., Gómez R., González C.A., Herrera L., López-Saura P.A., Perea-Rodríguez S.E., Santana A., Sigman H., Solares A.M., Thelvia I. Ramos Gómez, Valenzuela-Silva C.M.Fuentes:googlescopus